KRRO

Korro Bio Inc. (KRRO) | Rumor.io

Korro Bio

KRRO

Attention (50-day avg)0%

Attention rank (50-day avg)#3,336

Bullish sentiment (50-day avg)100%

Price to earnings ratio-0.76

Market capitalization140M

Earnings per share-9.87

Dividend yield (TTM)—

Revenue (annual)6.4M

Net income (annual)-117.3M

Social

What share of all stock conversation is about KRRO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Mar 13

Raymond James upgraded $KRRO to Outperform from Market Perform with a new price target of $23, citing strong preclinical data and high unmet need in hyperammonemia programs.
Cantor Fitzgerald maintained an Overweight rating on $KRRO and raised the price target from $21 to an unspecified new target, indicating positive momentum.
Insider buying activity has been reported, with multiple 10% owners purchasing 207,100 shares of $KRRO at $11.50 each, worth $2.30M.

Generated by AI

Sentiment

Of the messages about KRRO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	63.98% -27.57
Bearish	—	—	—	36.02% +27.57

Bullish· Mar 13

Insider buying activity has increased, with 9 insiders purchasing approximately $45M worth of shares on March 10, indicating confidence in the company's future prospects.
The company has secured a significant cash infusion through a PIPE deal, which will shore up its cash runway and reduce near-term financing overhang, allowing it to focus on key milestones.
Analysts are bullish on the company's pivot to hyperammonemia programs, with Raymond James upgrading its rating to Outperform and setting a new price target of $23, and Cantor Fitzgerald maintaining an Overweight rating with a raised price target of $21.

Bearish· Nov 14

Korro Bio, Inc. has not yet commercialized any product, resulting in no product revenue from sales.
The company has significant losses and a meaningful cash burn, with a net loss of ~$49.2 million and operating cash used of ~$43.7 million in the first six months of 2025.
Korro Bio, Inc. may need to raise additional capital before product revenue arrives, and they explicitly state there's no assurance they'll obtain financing on acceptable terms.

Generated by AI

Topics

Of the messages about KRRO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	32.02%
Technical Analysis	—	—	0%	8.13%
Analysts	—	—	0%	42.12%
Controversies	—	—	0%	1.35%
Earnings	—	—	0%	0.12%
Macro	—	—	0%	16.26%

Announcements· Mar 13

Korro Bio, Inc. (KRRO) announced its fourth quarter and full year 2025 financial results, with a corporate update also provided.
Insider buying activity has been significant in KRRO, with multiple large purchases of shares made by key stakeholders, including 10% owners and directors.
The insider buying activity has been interpreted as a sign of confidence in KRRO's future prospects, with some analysts suggesting that the purchases may be related to the company's cash runway and near-term financing overhang.

Technical Analysis· Jan 29

$KRRO has strong momentum, with buyers defending levels and pushing prices higher, potentially leading to continuation.
The technical setup suggests a favorable environment for Korro Bio, Inc. with momentum indicators supporting further upside.
Buyers are actively defending key levels, indicating a high level of interest and potential for further price appreciation in $KRRO.

Generated by AI

Community

Of the messages about KRRO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	97.56%	25.89%
Newcomers	—	100%	2.44%	74.11%

Mar 13

Insider buying is a positive signal, with 9 insiders purchasing a total of $45M worth of shares, with each insider spending around $2.3M.
Despite a recent earnings miss, Korro Bio's stock is up 4% after hours, and the insider buying cluster is a reason to watch the name.
The company's pivot into hyperammonemia indications, urea cycle disorders, and hepatic encephalopathy may improve its outlook, according to Ryan Deschner's positive view on the name.

Generated by AI

CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for...

1mo agoBarchart.com

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel...

1mo agoBarchart.com

Analysts Offer Insights on Healthcare Companies: Corbus Pharmaceuticals (CRBP) and Korro Bio (KRRO)

Detailed price information for Corbus Pharmaceuticals Hldgs Inc (CRBP-Q) from The Globe and Mail including charting and trades.

1mo agotheglobeandmail.com

Also Discussed

Investors talking about KRRO also mention

#	Name	Attention
1	Wave Life Sciences Ltd.WVE	0%+0
2	Baird Medical Investment Holdings Ltd.BDMD	0%new
3	Elicio Therapeutics Inc.ELTX	0%0
4	DBTX - Decibel Therapeutics, Inc.	——
5	SGTX - Sigilon Therapeutics, Inc.	——
6	TCRR - TCR2 Therapeutics Inc.	——
7	Citi Trends Inc.CTRN	0%0
8	Exagen Inc.XGN	0%new
9	ImageneBio, Inc.IKNA	0%0
10	IGMS - IGM Biosciences, Inc.	——

Korro Bio Inc.

Healthcare
Biotechnology

Korro Bio Inc. is a biopharmaceutical company focused on developing genetic medicines based on RNA editing. The company uses its proprietary OPERA platform, short for oligonucleotide promoted editing of RNA, to create therapies that make precise changes at the RNA level rather than permanently altering DNA. Its current pipeline centers on treatments for rare and highly prevalent diseases, with lead programs targeting liver-directed and other genetically defined conditions such as hyperammonemia, alpha-1 antitrypsin deficiency, and additional disorders with high unmet medical need. Korro Bio Inc. develops its candidates through discovery, preclinical, and clinical-stage research, combining RNA biology, oligonucleotide chemistry, and disease-specific design to generate differentiated therapeutic options. The company is headquartered in Cambridge, Massachusetts, and its work positions it within the growing field of next-generation genetic medicine.

Website

Location

60 First Street

Cambridge, MA, 02141

United States

Social

What share of all stock conversation is about KRRO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Mar 13

Raymond James upgraded $KRRO to Outperform from Market Perform with a new price target of $23, citing strong preclinical data and high unmet need in hyperammonemia programs.
Cantor Fitzgerald maintained an Overweight rating on $KRRO and raised the price target from $21 to an unspecified new target, indicating positive momentum.
Insider buying activity has been reported, with multiple 10% owners purchasing 207,100 shares of $KRRO at $11.50 each, worth $2.30M.

Generated by AI

Sentiment

Of the messages about KRRO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	63.98% -27.57
Bearish	—	—	—	36.02% +27.57

Bullish· Mar 13

Insider buying activity has increased, with 9 insiders purchasing approximately $45M worth of shares on March 10, indicating confidence in the company's future prospects.
The company has secured a significant cash infusion through a PIPE deal, which will shore up its cash runway and reduce near-term financing overhang, allowing it to focus on key milestones.
Analysts are bullish on the company's pivot to hyperammonemia programs, with Raymond James upgrading its rating to Outperform and setting a new price target of $23, and Cantor Fitzgerald maintaining an Overweight rating with a raised price target of $21.

Bearish· Nov 14

Korro Bio, Inc. has not yet commercialized any product, resulting in no product revenue from sales.
The company has significant losses and a meaningful cash burn, with a net loss of ~$49.2 million and operating cash used of ~$43.7 million in the first six months of 2025.
Korro Bio, Inc. may need to raise additional capital before product revenue arrives, and they explicitly state there's no assurance they'll obtain financing on acceptable terms.

Generated by AI

Topics

Of the messages about KRRO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	32.02%
Technical Analysis	—	—	0%	8.13%
Analysts	—	—	0%	42.12%
Controversies	—	—	0%	1.35%
Earnings	—	—	0%	0.12%
Macro	—	—	0%	16.26%

Announcements· Mar 13

Korro Bio, Inc. (KRRO) announced its fourth quarter and full year 2025 financial results, with a corporate update also provided.
Insider buying activity has been significant in KRRO, with multiple large purchases of shares made by key stakeholders, including 10% owners and directors.
The insider buying activity has been interpreted as a sign of confidence in KRRO's future prospects, with some analysts suggesting that the purchases may be related to the company's cash runway and near-term financing overhang.

Technical Analysis· Jan 29

$KRRO has strong momentum, with buyers defending levels and pushing prices higher, potentially leading to continuation.
The technical setup suggests a favorable environment for Korro Bio, Inc. with momentum indicators supporting further upside.
Buyers are actively defending key levels, indicating a high level of interest and potential for further price appreciation in $KRRO.

Generated by AI

Community

Of the messages about KRRO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	97.56%	25.89%
Newcomers	—	100%	2.44%	74.11%

Mar 13

Insider buying is a positive signal, with 9 insiders purchasing a total of $45M worth of shares, with each insider spending around $2.3M.
Despite a recent earnings miss, Korro Bio's stock is up 4% after hours, and the insider buying cluster is a reason to watch the name.
The company's pivot into hyperammonemia indications, urea cycle disorders, and hepatic encephalopathy may improve its outlook, according to Ryan Deschner's positive view on the name.

Generated by AI

Korro Bio

Social

Mar 13

Sentiment

Bullish· Mar 13

Bearish· Nov 14

Topics

Announcements· Mar 13

Technical Analysis· Jan 29

Community

Mar 13

News

Korro to Participate in Upcoming Investor Conferences

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Korro Bio director Jean Francois Formela sells $29,916 in shares

Lynx1 Capital, Korro Bio 10% owner, buys $78,809 in stock

All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy

Analysts Offer Insights on Healthcare Companies: Corbus Pharmaceuticals (CRBP) and Korro Bio (KRRO)

Also Discussed

Korro Bio Inc.

Company Information

Location

News

Korro to Participate in Upcoming Investor Conferences

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Korro Bio director Jean Francois Formela sells $29,916 in shares

Lynx1 Capital, Korro Bio 10% owner, buys $78,809 in stock

All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy

Analysts Offer Insights on Healthcare Companies: Corbus Pharmaceuticals (CRBP) and Korro Bio (KRRO)

Also Discussed

Social

Mar 13

Sentiment

Bullish· Mar 13

Bearish· Nov 14

Topics

Announcements· Mar 13

Technical Analysis· Jan 29

Community

Mar 13